Evoke Pharma Inc (EVOK)
5.86
+0.14
(+2.45%)
USD |
NASDAQ |
Nov 05, 16:00
5.75
-0.11
(-1.88%)
After-Hours: 18:51
Evoke Pharma Enterprise Value: 0.0252M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 0.0252M |
| November 01, 2024 | 0.084M |
| October 31, 2024 | 0.1207M |
| October 30, 2024 | 0.5616M |
| October 29, 2024 | 0.4514M |
| October 28, 2024 | 1.024M |
| October 25, 2024 | -0.2834M |
| October 24, 2024 | -0.4083M |
| October 23, 2024 | -0.4083M |
| October 22, 2024 | -0.2099M |
| October 21, 2024 | -0.1511M |
| October 18, 2024 | -0.1291M |
| October 17, 2024 | -0.2566M |
| October 16, 2024 | -0.401M |
| October 15, 2024 | -0.423M |
| October 14, 2024 | -0.4378M |
| October 11, 2024 | -0.3642M |
| October 10, 2024 | -0.2687M |
| October 09, 2024 | -0.3789M |
| October 08, 2024 | -0.085M |
| October 07, 2024 | -0.2246M |
| October 04, 2024 | -0.3201M |
| October 03, 2024 | -0.3569M |
| October 02, 2024 | -0.5406M |
| October 01, 2024 | -0.5994M |
| Date | Value |
|---|---|
| September 30, 2024 | -0.6802M |
| September 27, 2024 | -0.6434M |
| September 26, 2024 | -0.4451M |
| September 25, 2024 | -0.6508M |
| September 24, 2024 | -0.5038M |
| September 23, 2024 | -0.3128M |
| September 20, 2024 | -0.8639M |
| September 19, 2024 | -0.9153M |
| September 18, 2024 | -1.062M |
| September 17, 2024 | -0.9741M |
| September 16, 2024 | -1.076M |
| September 13, 2024 | -1.011M |
| September 12, 2024 | -1.099M |
| September 11, 2024 | -1.224M |
| September 10, 2024 | -1.165M |
| September 09, 2024 | -1.158M |
| September 06, 2024 | -1.334M |
| September 05, 2024 | -1.312M |
| September 04, 2024 | -1.246M |
| September 03, 2024 | -1.139M |
| August 30, 2024 | -1.026M |
| August 29, 2024 | -1.011M |
| August 28, 2024 | -0.9477M |
| August 27, 2024 | -0.8041M |
| August 26, 2024 | -0.7757M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.545M
Minimum
Nov 22 2022
142.35M
Maximum
Aug 14 2020
24.93M
Average
10.41M
Median
May 17 2022
Enterprise Value Benchmarks
| Repligen Corp | 7.600B |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 9.837M |
| Theriva Biologics Inc | -12.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.267M |
| Revenue (Quarterly) | 2.551M |
| Total Expenses (Quarterly) | 3.775M |
| EPS Diluted (Quarterly) | -11.16 |
| Gross Profit Margin (Quarterly) | 98.37% |
| Profit Margin (Quarterly) | -49.67% |
| Earnings Yield | -450.5% |
| Normalized Earnings Yield | -450.51 |